Pediatric Vaccine Market Report 2026

The pediatric vaccine market size has grown rapidly in recent years. It will grow from $57.51 billion in 2025 to $65.01 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to rising prevalence of preventable childhood diseases, government-led immunization campaigns, advancements in vaccine adjuvants, growing awareness of pediatric health, expansion of cold chain infrastructure.

The pediatric vaccine market size is expected to see rapid growth in the next few years. It will grow to $107.8 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to innovations in mRNA and DNA vaccines, increasing investment in pediatric vaccine R&D, digital health monitoring integration, expansion of emerging market healthcare infrastructure, partnerships between biotech firms and global health organizations. Major trends in the forecast period include increased focus on vaccine accessibility in low-income regions, rising adoption of combination vaccines, expansion of immunization programs in schools, development of novel pediatric vaccines for rare diseases, growing public-private partnerships in vaccine research.

The rising prevalence of chronic diseases such as tuberculosis, diphtheria, and pneumonia among children aged 15 years and below is contributing to the growth of the pediatric vaccines market. Children and adolescents with chronic conditions face an increased risk of severe disease outcomes and complications from infectious diseases. For example, in June 2024, the National Health Service (NHS) in the UK reported that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, an 18% increase from 3,065,825 cases in 2022. This rising prevalence of chronic diseases is therefore driving demand for pediatric vaccines.

The growing prevalence of pediatric diseases is expected to further propel the pediatric vaccine market in the coming years. Pediatric diseases, which affect children from infancy through puberty, can range from moderate to severe and may be chronic or acute. Pediatric vaccines play a vital role in preventing and controlling a wide range of these disorders, protecting newborns and children from various infectious illnesses. For example, in February 2024, GOV.UK reported that tuberculosis (TB) cases in England rose by 10.7% in 2023, from 4,380 cases in 2022 to 4,850. This increase in pediatric disease prevalence is driving demand in the pediatric vaccine market.

Major companies in the pediatric vaccine market are focusing on product approvals to better meet the needs of their consumers. ABRYSVO is a vaccine approved by the FDA for use in pregnant women to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in children up to six months old. For instance, in August 2023, Pfizer Inc., a US-based pharmaceutical company, announced FDA approval of ABRYSVO for the active immunization of pregnant women between 32 and 36 weeks of gestation. It is the first and only maternal vaccine approved in the United States to help protect newborns from LRTD and severe LRTD caused by RSV from birth to six months of age.

Major companies operating in the pediatric vaccine market are Merck & Co. Inc., Serum Institute of India Pvt. Ltd., Sanofi SA, Pfizer Inc., GlaxoSmithKline PLC, Sinovac Biotech Ltd, Zydus Cadila, Indian Immunologicals Limited, Panacea Biotec, Takeda Pharmaceutical Company, Daiichi Sankyo, CSL Limited, Sinopharm, Walvax Biotechnology, Fosun Pharma, MCM Vaccine Company, Seqirus, Johnson & Johnson, Connaught Laboratories Inc., Wyeth-Ayerst, Ataulfo de Paiva Foundation, Bio-Manguinhos - Institute of Technology on Immunobiologicals, Butantan Institute, Ezequiel Dias Foundation (FUNED), Sinergium.

North America was the largest region in the pediatric vaccine market in 2025. Middle East is expected to be the largest growing region in the global pediatric vaccine market share during the forecast period. The regions covered in the pediatric vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pediatric vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the pediatric vaccine market by increasing the cost of imported raw materials, adjuvants, and packaging components, which has affected production and supply chain efficiency. Vaccine manufacturers in Asia-Pacific and Europe, major suppliers of key biologics, are most affected by these tariff-related cost pressures. Certain high-value combination vaccines and rare disease vaccines face higher import duties, potentially slowing adoption in cost-sensitive regions. However, tariffs have also encouraged local production initiatives and investment in domestic manufacturing, supporting regional self-reliance and innovation in vaccine development.

The pediatric vaccine market research report is one of a series of new reports that provides pediatric vaccine market statistics, including pediatric vaccine industry global market size, regional shares, competitors with a pediatric vaccine market share, detailed pediatric vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the pediatric vaccine industry. This pediatric vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pediatric vaccines are medications administered to children to protect them against serious and often life-threatening diseases. These vaccines prepare the child’s body to respond more quickly and effectively by strengthening its natural defenses.

The main types of pediatric vaccines are monovalent and multivalent. Monovalent vaccines contain only a single antigen strain. The technologies used include live attenuated, inactivated, toxoid, conjugate, and others, providing immunity against infectious diseases, allergies, and cancer.

The pediatric vaccine market consists of sales of BCG vaccines, hepatitis B vaccines, pentavalent vaccines, and rotavirus vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.